Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FK45B
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,846
Award facts
- Contract value 100% obligated
- $42,846.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $42,846.23 for RINVOQ ER 15 MG tablets (30-count unit of use packaging) on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vehicle running through December 2026 that serves as the company's primary vehicle for supplying pharmaceutical products and medical commodities to support federal military and healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical vendor for the Defense Logistics Agency's Medical Supply Chain and serves the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a comprehensive range of medications and medical supplies across multiple therapeutic domains on a competitively awarded basis. RINVOQ ER (upadacitinib extended-release), a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, represents the specific pharmaceutical product being delivered under this delivery order to support federal military healthcare requirements.
Quick answers
Who was awarded contract SPE2DB25FK45B?
SPE2DB25FK45B was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FK45B worth?
The government has obligated $42,846 on SPE2DB25FK45B.
Is contract SPE2DB25FK45B an order under another contract?
Yes. SPE2DB25FK45B is a delivery order under SPE2DB20D1110, an indefinite delivery contract.
Was contract SPE2DB25FK45B competed?
The extent of competition for SPE2DB25FK45B was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award